Abstract | PURPOSE: SUMMARY: A 38-year-old female patient with a history of bipolar I disorder and TD secondary to atypical antipsychotic exposure developed worsening athetosis, hyperkinesia, and severe orofacial dyskinesia after initiation of ziprasidone. The patient had no improvement after discontinuation of atypical antipsychotics and required percutaneous endoscopic gastrostomy (PEG) placement for nutrition due to persistent aspiration and inability to tolerate oral nutrition. Despite a lack of information regarding administration of crushed deutetrabenazine tablets via PEG, that form of therapy was initiated and resulted in improvement of TD symptoms without noticeable adverse effects. CONCLUSION: TD can result in significant orofacial dyskinesia with impaired delivery of needed medications and nutrition. We describe a case in which a patient with severe TD and orofacial dyskinesia experienced improvement of symptoms with use of crushed deutetrabenazine. Larger studies to further evaluate use of crushed deutetrabenazine for treatment of TD are needed.
|
Authors | Jon P Wietholter, Jenna Sizemore, Kara Piechowski |
Journal | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
(Am J Health Syst Pharm)
Vol. 77
Issue 18
Pg. 1477-1481
(09 04 2020)
ISSN: 1535-2900 [Electronic] England |
PMID | 32761113
(Publication Type: Case Reports, Journal Article)
|
Copyright | © American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Antipsychotic Agents
- Tablets
- deutetrabenazine
- Tetrabenazine
|
Topics |
- Adult
- Antipsychotic Agents
(administration & dosage, adverse effects)
- Bipolar Disorder
(drug therapy)
- Female
- Gastrostomy
- Humans
- Severity of Illness Index
- Tablets
- Tardive Dyskinesia
(chemically induced, drug therapy)
- Tetrabenazine
(administration & dosage, analogs & derivatives)
|